Indeed, the authors found that cell lines transduced with a MET fusion gene were only tumorigenic on the background of a TP53 mutation, or deletion of CDKN2A/CDKN2B, suggesting that while dysregulation of the c-MET pathway plays a role in tumorigenesis, it alone is not sufficient to drive tumor growth (119). The gene discussed is MET; the disease is neoplasm.